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A b s T r A C T
Hereditary haemochromatosis (HH) is a disease related to 
mutations in the HFE gene and can lead to progressive iron 
accumulation, especially in the liver, eventually resulting 
in organ damage. We have developed guidelines for the 
diagnosis and treatment of this disease according to Cbo 
methodology (dutch institute for Healthcare Quality). 
The prevalence of clinical symptoms such as fatigue, 
arthropathies, impotence and diabetes mellitus among 
homozygotes was similar to that in a control population. 
Nevertheless, we recommend the assessment of serum iron 
indices when these symptoms remain unexplained. When 
transferrin saturation is >45% and ferritin exceeds local 
reference ranges, HFE mutations should be investigated. 
Homozygosity for the C282Y mutation or combined C282Y/
H63d mutation confirms the diagnosis of HFE-related 
HH. 
liver biopsy is recommended when ferritin exceeds 1000 
mg/l to establish the presence or absence of cirrhosis, which 
will affect prognosis and management. iron accumulation 
confirmed by magnetic resonance imaging (Mri) in 
the absence of the homozygous C282Y mutation or the 
combined C282Y/H63d genotype may justify a search 
for rare hereditary forms of non-HFE HH in a specialised 
centre. The literature supports the benefits of adequate 
phlebotomy and the screening of first-degree relatives 
of index patients with clinically overt HH. overall, the 
guidelines presented here are to a great extent based 
on the expert opinion of the working party, as the 
quantity of evidence that met predefined criteria posed 
by the evidence-based approach was small. We therefore 
recommend world-wide efforts to collaboratively address 
these remaining issues.
M E T H o d o l o G Y
development method 
The working group adopted the CBO (the Dutch 
Institute for Healthcare Quality, www.cbo.nl) method 
of evidence-based guideline development for answering 
a number of predefined clinical questions. A literature 
search exploiting MESH/(thesaurus) terms and free text 
in the databases Medline, Embase, and the Cochrane 
library was performed until mid 2005. Next to literature 
from systematic searches, additional articles were acquired 
by bibliographies of key reviews and included studies. 
Furthermore, relevant studies that appeared later than 2005 
were included, as well as (inter)national guidelines.1-6
Procedures
The concepts of the chapters of the guideline prepared by 
individual members of the working party on the basis of 
the best available evidence were discussed and amended in 
plenary sessions. Literature was reviewed and evidence was 
classified according to the CBO rating scheme. The members 
abstracted studies into evidence tables using condition 
definitions and diagnostic criteria. If scientific evidence 
was lacking, issues were discussed until the working party 
members agreed upon text and recommendations. 
The draft guideline was sent to the representing 
professional societies for comments. These comments 
were discussed by the working group and incorporated in 
the final version of the guideline. Two years after the first 
meeting of the working party, the guideline was approved 
by the boards of the participating scientific associations in 
May and June 2007 and made available on line along with 




d e c e m b e r  2 0 0 7 ,  V o l .  6 5 ,  N o .  1 1
Swinkels, et al. Guideline for the diagnosis and treatment of hereditary haemochromatosis.
figure 1. Diagnostic diagram for suspected iron accumulation
Ts = transferrin saturation; HH = hereditary haemochromatosis; Mri = magnetic resonance imaging.
*Type 1 diagnostics consists of testing the gene for rare mutations (i.e., not the frequent C282Y and H63d mutations). 
in addition to the information in the diagram, the diagnostic route taken may depend on:
Clinical presentation• 
Haemoglobin (low in secondary types of iron accumulation and in some forms of ferroportin disease)• 
family history (hereditary disease)• 
Concomitant clinical pictures (hepatitis, alcohol abuse)• 
Age upon presentation (young in the case of juvenile haemochromatosis)• 
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s U M M A r Y  o f  T H E  G U i d E l i N E
Epidemiology
Hereditary haemochromatosis (HH) is a disease that is 
characterised by progressive iron accumulation, especially 
in the liver, eventually resulting in organ damage. HH is a 
frequent hereditary condition. In Northern Europe, 0.5 to 1.0% 
of the population is homozygous for the C282Y mutation and 1 
to 3% has the combined C282Y/H63D genotype. However, the 
relation between genotype and the biochemical and clinical 
expression (reviewed in references 7-10) remains unclear. 
Morbidity
Iron accumulation results in a number of nonspecific 
symptoms, e.g. general health disturbance, joint problems, 
diabetes mellitus, fatigue, abdominal symptoms, impotence, 
cardiovascular diseases and skin pigmentation. However, none 
of these individual symptoms have been proved to occur more 
frequently among subjects with the genetic condition of HH 
than among control subjects. The occurrence of any of these 
symptoms, therefore, does not justify the performance of 
diagnostic tests for HH in first-line care. However, in accordance 
with international guidelines, the working group believes that 
assessment of the serum iron status should be considered in 
patients of Northern European descent who have been referred 
to a specialist after at least six months of unexplained symptoms 
as described above. The diagnostic diagram in figure 1 outlines 
the subsequent diagnostic and therapeutic strategies. 
diagnostic strategy
Serum iron indices
During the first diagnostic phase, the combined 
measurement of serum iron, transferrin (and the 
calculation of transferrin saturation (TS)) and ferritin, 
offers a simple and reliable approach for determining 
the amount of iron in the body. When TS is >45% and 
ferritin levels exceed the reference laboratory values, HFE 
mutations should be investigated. However, hyperfer-
ritinaemia and raised TS are observed both in HH and 
in secondary haemosiderosis with anaemia. Conditions 
with increased TS or ferritin but without significant iron 
accumulation including infections and inflammations, 
excessive alcohol use, hepatic disorders and metabolic 
syndrome should be considered. 
Genotypic testing
During the second diagnostic phase, homozygosity for the 
C282Y mutation or the combined C282Y/H63D genotype 
confirms an HFE-related form of HH. 
Role of liver biopsy and MRI
To diagnose cirrhosis a liver biopsy remains the gold standard 
and is recommended when serum ferritin is >1000 mg/l. In 
case of raised serum iron parameters without homozygosity 
for the C282Y mutation or the combined C282Y/H63D 
genotype, an MRI can be performed as a semiquantitative 
assessment of iron in the liver. MRI-confirmed iron 
accumulation in the absence of the C282Y mutation or the 
combined C282Y/H63D genotype justifies a search for rare 
hereditary forms of non-HFE HH in a specialised centre. 
f A M i l Y  s C r E E N i N G
In the third diagnostic phase, relatives to the first degree 
must be evaluated on the basis of iron parameters and, in 
the event of an HFE-related form of HH, on the basis of 
HFE genotyping as well. An index patient’s siblings and 
his children/parents have a 25 and 5% chance, respectively, 
of being predisposed to HH. 
T r E A T M E N T
The treatment of haemochromatosis involves phlebotomy, 
which can prevent and possibly reverse tissue damage. 
During the depletion phase, weekly 500 ml bloodlettings 
are performed based on haemoglobin and serum ferritin, 
until ferritin levels are less than 50 mg/l. During the 
maintenance phase, ferritin levels are kept within reference 
values, which may involve several phlebotomies per year. 
d i s C U s s i o N
Despite the wealth of information about this disease 
that has accumulated over the years, diagnostic and 
therapeutic strategies that are recommended in the various 
reviews throughout the literature as well in our and other 
guidelines appear to lack solid evidence and are to a great 
extent based on expert opinions. 
During the development of the guidelines, we identified the 
following parts in the work-up and treatment of patients that 
in our opinion urgently need a more solid scientific basis:
• the natural history of the relation between genotype and 
phenotype in the disease, with respect to sex, age, and 
genetic and environmental factors;
• determination of the optimal approach to screening for 
iron overload;
• the level of the serum iron indices above which disease 
manifestations as fatigue and arthritis are likely to occur; 
• the substantial interlaboratory variation of the ferritin 
value;
• the target value of the serum iron indices during both 
the depletion and the maintenance phase of phlebotomy 
treatment.
We therefore recommend world-wide efforts to 
collaboratively address these issues.
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N o T E
The guideline development was initiated by the 
Netherlands Association of Interal Medicine (NIV), 
the Netherlands Society of Clinical Chemistry and the 
Laboratory Medicine (NVKC) and Laboratory Diagnostic 
Practitioners Association (VAL). 
The guidelines were developed within the framework of the 
EBRO (Evidence Based Guideline Development) Programme 
of the Order of Medical Specialists in association with the 
Dutch Society for Gastroenterology (MDL), Dutch College 
of General Practitioners (NHG), Dutch Blood Transfusion 
Society (NVB), Dutch Society for Haematology (NVvH), 
Dutch Society for Pathology (NVVP), Dutch Society for 
Radiology (NVvR), Dutch Society for Reumatology (NVvR), 
Dutch Society for Clinical Genetics (VKGN) and the 
Haemochromatosis Society the Netherlands (HVN). Support 
was provided by the Committee for Guideline Development 
of the Netherlands Association of Internal Medicine and the 
Dutch Institute for Healthcare Quality CBO. 
The target audience for this guideline is the Dutch 
professionals in their management of patients and their 
relatives with hereditary haemochromatosis, including 
general practitioners, internists, gastroenterologists, 
rheumatologists, radiologists, haematologists, clinical 
pathologists, clinical chemists and clinical geneticists. 
The working party consisted of the following people:
Dr D.W. Swinkels, clinical chemist and laboratory • 
physician, Radboud University Nijmegen Medical 
Centre, Nijmegen, the Netherlands, Chairperson 
A.T.M. Jorna, internist, the Netherlands Association • 
of Interal Medicine, Domus Medica, Utrecht, the 
Netherlands, advisor and secretary, Committee 
Guideline Development the Netherlands Association 
of Internal Medicine
Dr R.A.P. Raymakers, internist-haematologist, Radboud • 
University Nijmegen Medical Centre, Nijmegen, the 
Netherlands
M.A. van Bokhoven, general practitioner, Maastricht • 
University, Maastricht, the Netherlands
Dr A. Castel, clinical chemist, Bronovo Hospital, The • 
Hague, the Netherlands
Dr C.T.B.M. van Deursen, internist, Atrium Medical • 
Centre, Heerlen, the Netherlands
Dr J.C. Giltay, clinical geneticist, University Medical • 
Centre Utrecht, Utrecht, the Netherlands 
Professor J.H.J.M. van Krieken, pathologist, Radboud • 
University Nijmegen Medical Centre, Nijmegen, the 
Netherlands
Dr J.D. Macfarlane, rheumatologist, Westeinde Hospital, • 
The Hague, the Netherlands
Dr R.A. de Man, gastroenterologist, Erasmus Medical • 
Centre, Rotterdam, the Netherlands
Professor J.J.M. Marx, internist, University Medical • 
Centre Utrecht, Utrecht, the Netherlands
Dr M.E.J. Pijl, radiologist, Martini Hospital, Groningen, • 
the Netherlands
P. de Sterke, MSc, representative Dutch Haemo -• 
chromatosis Society
Dr R.A. de Vries, gastroenterologist, Rijnstate Hospital, • 
Arnhem, the Netherlands
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